Janus Henderson Group
SAGE

Janus Henderson Group’s Sage Therapeutics SAGE Stock Holding History

Janus Henderson Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,893
Closed -$140K – 2541
2024
Q4 		$140K Hold
25,893
– – ﹤0.01% 2490
2024
Q3 		$187K Hold
25,893
– – ﹤0.01% 2447
2024
Q2 		$281K Sell
25,893
-266
-1% -$3.41K ﹤0.01% 2237
2024
Q1 		$490K Hold
26,159
– – ﹤0.01% 2016
2023
Q4 		$567K Sell
26,159
-40
-0.2% -$793 ﹤0.01% 1931
2023
Q3 		$539K Buy
26,199
+4
+0% +$116 ﹤0.01% 1884
2023
Q2 		$1.23M Sell
26,195
-392,551
-94% -$19.5M ﹤0.01% 1500
2023
Q1 		$17.6M Sell
418,746
-200,544
-32% -$8.62M 0.01% 600
2022
Q4 		$23.6M Sell
619,290
-112,133
-15% -$4.28M 0.02% 534
2022
Q3 		$28.6M Sell
731,423
-35,626
-5% -$1.38M 0.02% 486
2022
Q2 		$24.8M Sell
767,049
-262,904
-26% -$8.81M 0.02% 523
2022
Q1 		$34.1M Buy
1,029,953
+54,971
+6% +$2.07M 0.02% 606
2021
Q4 		$41.5M Sell
974,982
-76,011
-7% -$3.18M 0.02% 606
2021
Q3 		$46.6M Sell
1,050,993
-609,460
-37% -$27.9M 0.02% 573
2021
Q2 		$94.3M Sell
1,660,453
-212,929
-11% -$15.1M 0.04% 386
2021
Q1 		$140M Sell
1,873,382
-105,429
-5% -$8.64M 0.06% 293
2020
Q4 		$171M Buy
1,978,811
+359,110
+22% +$26.5M 0.08% 252
2020
Q3 		$99M Buy
1,619,701
+160,025
+11% +$8.11M 0.05% 330
2020
Q2 		$60.7M Buy
1,459,676
+71,881
+5% +$2.61M 0.03% 442
2020
Q1 		$39.9M Sell
1,387,795
-1,026,417
-43% -$59.4M 0.03% 514
2019
Q4 		$174M Buy
2,414,212
+398,808
+20% +$49.1M 0.09% 250
2019
Q3 		$283M Buy
2,015,404
+141,996
+8% +$23.8M 0.15% 161
2019
Q2 		$343M Buy
1,873,408
+204,779
+12% +$34.9M 0.19% 135
2019
Q1 		$265M Buy
1,668,629
+1,359,947
+441% +$197M 0.15% 173
2018
Q4 		$29.6M Buy
308,682
+44,019
+17% +$5.04M 0.02% 654
2018
Q3 		$37.4M Buy
264,663
+87,427
+49% +$13.5M 0.02% 659
2018
Q2 		$27.7M Sell
177,236
-7,413
-4% -$1.16M 0.02% 717
2018
Q1 		$29.7M Sell
184,649
-12,386
-6% -$2.1M 0.02% 693
2017
Q4 		$32.5M Buy
+197,035
New +$19.1M 0.02% 645

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Janus Henderson Group's SAGE Position: Q1 2025 in Review

Janus Henderson Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 25,893 shares — an estimated $140K sold.

Janus Henderson Group first reported a position in SAGE in Q4 2017 and held it in 29 quarters. The position peaked at $343M in Q2 2019. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Janus Henderson Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janus Henderson Group sold 25,893 Sage Therapeutics shares in Q1 2025, an estimated $140K.
  • Janus Henderson Group first reported a position in Sage Therapeutics in Q4 2017 and held it in 29 quarters.
  • Janus Henderson Group's Sage Therapeutics position peaked at $343M in Q2 2019.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Janus Henderson Group's 13F filing for Q1 2025, filed 15 May 2025.